GlassScriptPhysician profile
Jeremy Breit
NPI 1275538944
$4,053.67
in general payments reported to CMS, 2019-2025
32 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $327 · 2021: $115 · 2022: $84.66 · 2023: $32.64 · 2024: $608 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955 · Travel and Lodging: $329 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.94 |
| Travel and Lodging | $328.88 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $733.31 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.78 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $435.03 | 2019-2025 | Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $333.24 | 2025 | |
| Mylan Specialty L.P. | $246.20 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $192.69 | 2019-2025 | Dupixent |
| Insmed, INC. | $189.71 | 2019-2025 | Arikayce |
| Verona Pharma, INC. | $188.78 | 2025 | Ohtuvayre |
| Genzyme Corporation | $187.66 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $146.45 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $146.32 | 2019-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $120.74 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $115.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $88.34 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.95 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $53.16 | 2022 | |
| Grifols USA, LLC | $41.49 | 2019-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $39.41 | 2025 | Yupelri |
| Amgen INC. | $31.38 | 2024 | Tavneos |
| Merck Sharp & Dohme LLC | $30.92 | 2019 | |
| Ani Pharmaceuticals, INC. | $29.01 | 2024 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $23.40 | 2020 | |
| Baxter Healthcare | $22.43 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $18.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.65 | 2019 | |
| La Jolla Pharmaceutical Company | $16.65 | 2019 | |
| Allergan, INC. | $15.75 | 2019 | |
| Horizon Therapeutics Plc | $15.71 | 2019 | |
| Circassia INC. | $14.61 | 2019 | |
| Ekos Corporation | $14.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.30 | 2019 | |
| Inogen, INC. | $9.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Breit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.